Medications for Female Sexual Interest/Arousal Disorder

Medications for Female Sexual Interest/Arousal Disorder

Medication

Dose

Outcomes

Adverse Effects

Prescribing Considerations

Flibanserin

100 mg orally at bedtime daily

Increase in sexual desire and satisfying sexual events

Dizziness, somnolence, nausea, fatigue

FDA-approved for use in premenopausal women. Not approved for use in postmenopausal women; however, studies show similar safety and efficacy.

Bremelanotide

1.75 mg subcutaneous injection self-administered as needed 45 minutes before sexual activity

Increase in sexual desire

Decrease in sexual distress 

Nausea/vomiting, flushing, injection site reaction, headache

FDA-approved for use in premenopausal women

Bupropion

300–400 mg daily taken orally 

Increase in sexual desire

Tremor, agitation, dry mouth, constipation, excessive sweating, dizziness, nausea/vomiting

Sometimes prescribed off-label.

Buspirone

20–60 mg daily taken orally

Increase in sexual desire in patients with clinical depression and medication-induced sexual dysfunction

Dizziness, nervousness, nausea, headache

Sometimes prescribed off-label for treatment of FSIAD in patients with SSRI–induced sexual dysfunction (coadminister)

Trazadone

3.5 mg daily taken orally

Increase in sexual desire

Drowsiness, dry mouth, nausea, headache

At high doses, can cause persistent genital arousal disorder

Sometimes prescribed off-label for treatment of FSIAD

Systemic estrogen therapy

Comes in numerous formulations and dosages (transdermal patches, vaginal rings, topical gel, spray)

Increase in sexual desire and arousal with transdermal formulations

Oral formulations should be avoided due to increase in sex hormone binding globulin

Nausea, breast tenderness, headache, bloating, postmenopausal bleeding

Sometimes prescribed off-label for treatment of FSIAD in postmenopausal women

Not used for this FSIAD in premenopausal women.

Testosterone

5 mg testosterone/5 g gel

0.5 mL applied daily to inner thigh or underarm

Increase in sexual desire and satisfying sexual events

Decrease in sexual distress

Hirsutism, acne, virilization (clitoromegaly, balding, voice deepening)

Used off-label (no commercially available formulations for women)

Testosterone measurements are recommended at baseline, then 3 months and every 6 months to maintain levels within normal range for reproductive-age women

FDA = Food and Drug Administration; FSIAD = female sexual interest/arousal disorder ; SHBG = sex hormone binding globulin; SSRI = selective serotonin reuptake inhibitor;

FDA = Food and Drug Administration; FSIAD = female sexual interest/arousal disorder ; SHBG = sex hormone binding globulin; SSRI = selective serotonin reuptake inhibitor;